GastroHep / 2023 / Article / Tab 1 / Research Article
Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study Table 1 Patient demographics and clinical characteristics. Full details in supplement C.
UC cohort CD cohort Complete cohort Total number 28 105 133 Age—median (range) (years) 43 (19-74) 38 (18-90) 38 (18-90) Male/female—no. (%) 16 (57.1)/12 (42.9) 58 (55.2)/47 (44.8) 74 (55.6)/59 (44.4) Race—no. (%) (i) White 24 (85.7) 99 (94.3) 123 (92.5) (ii) Mixed 0 (0) 0 (0) 0 (0) (iii) Asian or Asian background 1 (3.6) 4 (3.8) 5 (3.8) (iv) Black or Black British 3 (10.7) 2 (1.9) 5 (3.8) (v) Chinese 0 (0) 0 (0) 0 (0) (vi) Other 0 (0) 0 (0) 0 (0) BMI—median (range) 26.5 (19.7–40.2) 25.4 (16.6-48.4) 25.9 (16.6-48.4) Smoking status—no. (%) (i) Never 21 (75.0) 52 (49.5) 73 (54.9) (ii) Current 0 (0) 22 (21.0) 22 (16.5) (iii) Previous 7 (25) 31 (29.5) 38 (28.6) Vaping status—no. (%) (i) Never 26 (92.9) 97 (92.4) 123 (92.5) (ii) Current 2 (7.1) 7 (6.7) 9 (6.8) (iii) Previous 0 (0) 1 (1.0) 1 (0.8) Duration of disease—median (range) (years) 3 (0-38) 8 (0-36) 7 (0-38) Age at onset—no. (%) (i) A1: <16 8 (7.6) (ii) A2: 17-40 78 (74.3) (iii) A3: >40 19 (18.1) Site of Crohn’s disease—no. (%) (i) L1: ileal 25 (23.8) (ii) L2: colonic 30 (28.6) (iii) L3: ileocolonic 50 (47.6) (iv) L4: upper GI tract 4 (3.8) Crohn’s disease behaviour—no. (%) (i) B1: nonstricturing/nonpenetrating 65 (61.9) (ii) B2: stricturing 16 (15.2) (iii) B3: penetrating 24 (22.9) (iv) p: perianal disease 17 (16.2) Site of ulcerative colitis—no. (%) (i) E1: proctitis 0 (0) (ii) E2: left sided 14 (50.0) (iii) E3: extensive 14 (50.0) Concomitant medications at baseline—no. (%) (i) Azathioprine/mercaptopurine 11 (39.3) 56 (53.3) 67 (50.4) (ii) Methotrexate 6 (21.4) 14 (13.3) 20 (15.0) Previous biologic history—no. (%) (i) Remicade 7 (25.0) 45 (42.9) 52 (39.1) (ii) Adalimumab 3 (10.7) 16 (15.2) 19 (14.3)